A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

Phase II trial of the novel combination, decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Secondary Acute Myeloid Leukemia.

BYON-4413 is under clinical development by Byondis and currently in Phase I for Refractory Acute Myeloid Leukemia.

On Friday, groups of preschoolers cycled Lake Havasu High School’s hallways for childhood cancer. The event is part of the ...